Our Services
Medical Information
Helpful Resources
Published on: 9/22/2026
Cyclobenzaprine (Flexeril, Amrix) is a prescription muscle relaxant used short term, usually 2 to 3 weeks, to ease muscle spasms, stiffness, and pain from acute strains, sprains, back or neck injuries, and it is sometimes prescribed off label for fibromyalgia or tension headaches. A single immediate release dose typically starts working within about 1 hour, lasts roughly 4 to 6 hours, and is dosed up to three times daily, while the extended release capsule lasts about 24 hours; the drug's half life ranges from about 8 to 37 hours, so it can linger in your system for several days and cause next day drowsiness. How long the effects last for you depends on several factors, including your age, liver function, dose and formulation, alcohol use, and other medications such as opioids, benzodiazepines, antidepressants, or MAO inhibitors, so see below for the important details and warnings you should consider before taking it. Because muscle spasms can stem from anything from a minor strain to a pinched nerve, disc problem, or another underlying condition, knowing what is actually causing your pain matters more than just masking it. Take a free, instant, online symptom check to better understand what may be driving your symptoms and to get clear guidance on your next steps.
Last reviewed for medical accuracy: 09/22/2026
Cyclobenzaprine is a prescription muscle relaxant commonly used to help ease muscle spasms and the pain that comes with them. It’s often part of a broader treatment plan that includes rest, physical therapy, and other measures.
Cyclobenzaprine belongs to a class of drugs known as skeletal muscle relaxants. Though its exact mechanism isn’t fully understood, it appears to work on the central nervous system (CNS) to reduce muscle hyperactivity. It does not act directly on the muscles themselves, but rather at brainstem levels to decrease the signals that cause spasms.
Cyclobenzaprine is primarily prescribed for:
Off-label uses (based on clinical judgment) may include certain types of fibromyalgia or chronic tension headache, but these are not formally approved by regulatory agencies.
Cyclobenzaprine is available in two main formulations:
Immediate-Release Tablets
Extended-Release Capsules (Amrix®)
Your doctor will choose the form and dose based on factors like the severity of your spasms, other medical conditions, and how you respond to treatment.
Understanding how long you’ll feel relief involves several points:
Most side effects are mild to moderate and tend to improve as your body adjusts:
If you experience persistent or bothersome effects, talk to your doctor about adjusting the dose or trying an alternative.
Before starting cyclobenzaprine, let your doctor know if you have any of the following:
Cyclobenzaprine can amplify the effects of alcohol and other CNS depressants (e.g., benzodiazepines, opioids). Avoid driving or operating machinery until you know how this medication affects you.
Cyclobenzaprine interacts with several medications. Key ones to mention:
Always provide a full list of your current medications and supplements to your doctor or pharmacist.
An overdose of cyclobenzaprine can be serious. Symptoms may include extreme drowsiness, confusion, fast or slow heart rate, seizures, or loss of consciousness. If you suspect an overdose, seek emergency medical attention right away.
Muscle relaxants like cyclobenzaprine are generally safe when used as directed. However, you should contact a healthcare professional if you experience:
For a simple way to get started, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker
. It can help you decide whether to seek immediate medical care or discuss options with your primary doctor.
Always speak to a doctor about anything that could be serious or life-threatening. Your healthcare provider can help you decide if cyclobenzaprine is right for you, recommend alternative treatments, and monitor you for side effects. If you’re unsure where to start, try a free, online symptom check, using the doctor approved Ubie Symptom Checker
to guide your next steps.
(References)
* Winchell GA, King JD, Chavez-Eng CM, Constanzer ML, Korn SH. Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. J Clin Pharmacol. 2002 Jan;42(1):61-9. doi: 10.1177/0091270002042001007. PMID: 11808825.
* Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. doi: 10.1016/j.jpainsymman.2004.05.002. PMID: 15276195.
* See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008 Feb;28(2):207-13. doi: 10.1592/phco.28.2.207. PMID: 18225966.
* Gai MN, Costa E, Arancibia A. Bioavailability of a controlled-release cyclobenzaprine tablet and influence of a high fat meal on bioavailability. Int J Clin Pharmacol Ther. 2009 Apr;47(4):269-74. doi: 10.5414/cpp47269. PMID: 19356393.
* Brioschi TM, Schramm SG, Kano EK, Koono EE, Ching TH, Serra CH, Porta V. Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. Biomed Res Int. 2013;2013:281392. doi: 10.1155/2013/281392. Epub 2013 Sep 16. PMID: 24151591; PMCID: PMC3787571.
* Adar L, Zarycranski W, Conner JB, Dragone J, Janka L, Rabinovich-Guilatt L. Bioequivalence of cyclobenzaprine hydrochloride extended-release capsule taken intact or sprinkled over applesauce . Int J Clin Pharmacol Ther. 2017 Dec;55(12):931-938. doi: 10.5414/CP203059. PMID: 29092731.
* Mina D, Johansen KL, McCulloch CE, Steinman MA, Grimes BA, Ishida JH. Muscle Relaxant Use Among Hemodialysis Patients: Prevalence, Clinical Indications, and Adverse Outcomes. Am J Kidney Dis. 2019 Apr;73(4):525-532. doi: 10.1053/j.ajkd.2018.11.008. Epub 2019 Jan 11. PMID: 30639233.
* Buyukgoz C, Gangu S, Gowani F, Kimura D. Treatment of comatose patient from cyclobenzaprine overdose with therapeutic plasma exchange. J Clin Apher. 2022 Jun;37(3):313-315. doi: 10.1002/jca.21960. Epub 2021 Dec 25. PMID: 34953071.
* Miranda Dos Santos E, Ferraz HG, Issa MG, Duque MD. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space. J Pharm Sci. 2023 Dec;112(12):3131-3140. doi: 10.1016/j.xphs.2023.07.012. Epub 2023 Jul 19. PMID: 37473918.
* Shah CR, Patel SR, Bhatt LK, Rajwadi VI, Patel UP, Kadu H, Patel JH, Patel H, Ranvir RK, Sundar R, Laddha RN, Jain MR. Preclinical safety, tolerability and pharmacokinetics of a novel cyclobenzaprine hydrochloride nasal spray. Regul Toxicol Pharmacol. 2025 Dec;163:105930. doi: 10.1016/j.yrtph.2025.105930. Epub 2025 Aug 25. PMID: 40865761.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.